Shots: FDA’s PDAC & DSaRM has jointly voted (14 yes, 2 no, 1 abstain) for favorable benefit-risk profile of Spravato (esketamine) nasal spray C-III, based on five P-III studies (including […]readmore
Tags : Advisory Committees